Novo Sees Brighter China Outlook As Volumes Rise
Executive Summary
Novo Nordisk says its China business is regaining strength, helped by improved volumes and broad growth in the diabetes sector and despite pricing pressures, and sees a brighter outlook ahead of the local approval of Tresiba.
You may also be interested in...
2017 Preview: Fresh Concerns And New Hopes In China
If 2016's Year of the Monkey was a period of ups and downs in China, filled with a series of rapid changes in regulations and plans for overseas expansion by domestic pharma companies, 2017's Year of the Rooster is likely to be even more uncertain, industry insiders say.
Kyowa Kirin’s Parkinson’s Successor Shows Phase IIb Promise
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Asia Deal Watch: Rhizen Licenses Chinese Rights For PI3K Inhibitor To Curon
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Need a specific report? 1000+ reports available
Buy Reports